Extended Postexposure Protection Against Vaginal Simian/Human Immunodeficiency Virus Infection With Tenofovir Alafenamide Fumarate/Elvitegravir Inserts in Macaques.
Natalia MakarovaTyana SingletaryM Melissa PeetJames MitchellShanon BachmanAngela HolderChuong DinhJonathan LipscombVivek AgrahariMaria MendozaYi PanWalid HeneineMeredith R ClarkJ Gerardo Garcίa-LermaGustavo F DoncelJames M SmithPublished in: The Journal of infectious diseases (2024)
Vaginal inserts that can be used on demand before or after sex may be a desirable human immunodeficiency virus (HIV) prevention option for women. We recently showed that inserts containing tenofovir alafenamide fumarate (TAF, 20 mg) and elvitegravir (EVG, 16 mg) were highly protective against repeated simian/human immunodeficiency virus (SHIV) vaginal exposures when administered to macaques 4 hours before or after virus exposure (93% and 100%, respectively). Here, we show in the same macaque model that insert application 8 hours or 24 hours after exposure maintains high efficacy (94.4% and 77.2%, respectively). These data extend the protective window by TAF/EVG inserts and inform their clinical development for on-demand prophylaxis in women.
Keyphrases
- human immunodeficiency virus
- antiretroviral therapy
- hiv infected
- hepatitis c virus
- polycystic ovary syndrome
- hiv positive
- hiv aids
- endothelial cells
- pregnancy outcomes
- cervical cancer screening
- electronic health record
- air pollution
- big data
- induced pluripotent stem cells
- type diabetes
- adipose tissue
- machine learning
- skeletal muscle